/PRNewswire/ Digital Therapeutics (DTx) Market in terms of revenue was estimated to be worth $6.1 billion in 2023 and is poised to reach $21.9 billion by.
Better Therapeutics (BTTX) Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Over a lifetime horizon AspyreRx plus standard of care was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost
Study suggests that.
Better Therapeutics (BTTX) and Glooko Partner to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the US streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Better Therapeutics (BTTX) Submits FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.